SCYNEXIS,公司(“公司該協議(「協議」)是與Citigroup Global Markets Inc.,Barclays Capital Inc.,Wedbush Securities Inc.,Northland Securities,Inc. and Ladenburg Thalmann Co. Inc.(各自爲「花旗集團」,「巴克萊銀行」,「Wedbush證券」,「北國證券」和“Ladenburg Thalmann“,並統稱爲「全球貨幣」)達成的。協議”)與康特-費哲傑& Co.(“Cantor如下所示:
1.
股份發行和銷售公司同意,在本協議期間,根據本協議規定的條款和條件,可能不時通過作爲代理商的康朵公司發行和出售公司的普通股股票,每股面值爲0.001美元(“普通股”); 在每種情況下,該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時;, 但是在任何情況下,公司均不得通過康朵公司發行或出售數量或金額達到指定的普通股股票數量或金額(根據本協議出售或將要出售的普通股股票統稱爲“ “定向增發股份”)(a)超過根據正在進行的有效註冊聲明(下文定義)註冊的數量或金額,(b)超過公司已發行但尚未發行的普通股數量(減去公司已發行的或通過任何已發行證券的行使、轉換或交換或其他方式從公司授權的股本中保留的普通股數量),(c)超過根據S-3表格允許出售的普通股數量或金額(包括一般指示I.b.6所述內容,如適用)或(d)超過公司已提交招股說明書(下文定義)的普通股數量或金額(a)、(b)、(c)和(d)中較小的數量或金額,爲“此處爲最高利潤”). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this 第1節 和 5(c) on the number or dollar amount of shares of Common Stock issued and sold under this Agreement shall be the sole responsibility of the Company, and Cantor shall have no obligation in connection with such compliance. The offer and sale of Placement Shares through Cantor will be effected pursuant to the Registration Statement filed or to be filed by the Company and which has been or will be declared effective by the Securities and Exchange Commission (the “委員會:”), although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue the Common Stock.
The Company has filed or will file, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the “證券法公司已準備或將準備一份擬作爲S-3表格登記聲明的註冊聲明,包括一份基本的招股說明書,涉及某些證券,包括公司不時發行的普通股,該註冊聲明引入公司已經或將按照相關規定提交的文件
不時以書面形式修改。發售通知一經Cantor收到即生效,除非(i)根據 (a)委員會負責管理本《2023年計劃》,並可以將其職責和權力全部或部分委託給任何子委員會。 委員會可以制定本《2023年計劃》的規則和條例。 委員會應按其所確定的時間和地點召開會議。 委員會成員中的多數人構成法定人數。, Cantor declines to accept the terms contained therein for any reason, in its sole discretion, (ii) the entire amount of such Placement Shares have been sold, (iii) in accordance with the notice requirements set forth in (a)委員會負責管理本《2023年計劃》,並可以將其職責和權力全部或部分委託給任何子委員會。 委員會可以制定本《2023年計劃》的規則和條例。 委員會應按其所確定的時間和地點召開會議。 委員會成員中的多數人構成法定人數。, the Company suspends or terminates the Placement Notice, (iv) the Company issues a subsequent Placement Notice with parameters superseding those on the earlier dated Placement Notice, or (v) the Agreement has been terminated under the provisions of 第11節. 修改和終止。
(a) 除適用法律禁止的範圍外,並且除非獎項協議或本2020年計劃另有明示規定,行政管理者可隨時修改、改變、暫停、停止或終止本2020年計劃或此事項或此類事項的一部分;. The amount of any discount, commission or other compensation to be paid by the Company to Cantor in connection with the sale of such Placement Shares shall be calculated in accordance with the terms set forth in 附表3. It is expressly acknowledged and agreed that neither the Company nor Cantor will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to Cantor and Cantor does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control.
3.
Sale of Placement Shares by Cantor. Subject to the terms and conditions herein set forth, upon the Company’s delivery of a Placement Notice, and unless the sale of the Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, Cantor, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Stock Market, Inc. (“納斯達克資本市場”) to sell such Placement Shares up to the amount specified in, and otherwise in accordance with the terms of, such Placement Notice. Cantor will provide written confirmation to the Company (including by email correspondence to each of the individuals of the Company set forth on 時間表2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the volume-weighted average price of the Placement Shares sold, and the Net Proceeds (as defined below) payable to the Company. Cantor may sell Placement Shares by any method permitted by law deemed to be an 「at the market offering」 as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or through Nasdaq, on any other existing trading market for the Common Stock or to or through a market maker. If expressly authorized by the Company in a Placement Notice, Cantor may also sell Placement Shares in negotiated transactions. Notwithstanding the provisions of Section 6(aaa), Cantor shall not purchase Placement Shares for its own account as principal unless expressly authorized to do so by the Company in a Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance that Cantor will be successful in selling Placement Shares, and (ii) Cantor will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by Cantor to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such Placement Shares as required under this 第3章。資格.在本文中,「sell」表示除TD考溫的商業上合理努力與正常交易和銷售慣例一致以達到出售這些股票的目的外的任何行爲。交易日「交易日」指公司普通股在其上市或掛牌的主要市場上購買和出售的任何一天。
Notwithstanding any other provision of this Agreement, during any period in which the Company is in possession of material non-public information, the Company and Cantor agree that (i) no sale of Placement Shares will take place, (ii) the Company shall not request the sale of any Placement Shares, and (iii) Cantor shall not be obligated to sell or offer to sell any Placement Shares.
(c)
If, any time after the exemptive provisions set forth in Rule 101(c)(1) of Regulation m under the Exchange Act (“規則M”) become applicable to the Company, either Cantor or the Company has reason to believe that such exemptive provisions are not satisfied with respect to the Common Stock, it shall promptly notify the other party, and Cantor may, at its sole discretion, suspend sales of the Placement Shares under this Agreement.
5.
結算.
(a)
配售股份的清算. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares by Cantor will occur on the first (121世紀醫療改革法案)。安置代理應在下一交易日開盤之前,以書面形式(包括通過電子郵件通函發送給附表B中所列個人)通知公司已銷售的安置證券的每次銷售。在結算日期交付給公司的款項(“結算日”). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of such Placement Shares sold (the “淨募資”) will be equal to the aggregate sales price received by Cantor at which such Placement Shares were sold, after deduction for (i) Cantor’s commission, discount or other compensation for such sales payable by the Company pursuant to 第2節 hereof, (ii) any other amounts due and payable by the Company to Cantor hereunder pursuant to 第7(g)節 (Expenses) hereof, and (iii) any transaction fees imposed by any Governmental Authority (as defined below) in respect of such sales.
(b)
認購股份的交接. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Placement Shares being sold by Cantor by crediting Cantor’s or its designee’s account (provided Cantor shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by the parties hereto which in all cases shall be freely tradeable, transferable, registered shares in good deliverable form. On each Settlement Date, Cantor will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to, the Settlement Date. Cantor will be responsible for providing DWAC instructions or instructions for delivery by other means with regard to the transfer of such Placement Shares being sold. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver duly authorized Placement Shares on a Settlement Date (other than as a result of a failure by Cantor to provide instructions for delivery), the Company agrees that in addition to and in no way limiting the rights and obligations set forth in 本條款第9(a)節(公司承擔義務賠償)規定的權利和義務之外,如果公司或其代理未能履行在交割日交付授權股份的義務而不是由於TD Cowen的原因,公司同意(i)保護TD Cowen免失或對TD Cowen遭受的任何損失、索賠、損害、合理且可證明的費用(包括律師費和其他費用)承擔責任,並(ii)支付任何佣金、折價或其他報酬給TD Cowen(無需重複)。如未發生違約情況,TD Cowen將享有按照協議應得到的佣金、折價或其他報酬。 (Indemnification and Contribution) hereto, it will (i) hold Cantor harmless against any loss, claim, damage, or reasonable, documented expense (including
4
reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default by the Company and (ii) pay to Cantor (without duplication) any commission, discount, or other compensation to which it would otherwise have been entitled absent such default.
(c)
發行規模的限制. In no event shall the Company issue or sell through Cantor such number or dollar amount of Placement Shares that would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the Maximum Amount and (B) the amount authorized from time to time to be issued and sold under this Agreement by the Company’s board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to Cantor in writing. Further, under no circumstances shall the Company cause or permit the aggregate offering amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.
公司已合法成立,並且在設立公司的管轄區域法律下是有效的開曼群島免稅公司,在公司的設立管轄區域法律下處於良好的經營狀況(在存在這種概念的情況下),並擁有設立、租賃和經營其財產以及在本註冊聲明、銷售時間的展望和招股說明書中所述的業務的權力和權限,並且有能力履行其在本協議項下的義務。公司已合法取得外國公司的資格,以在要求的任何司法管轄區內開展業務,並且在要求的任何司法管轄區內處於良好的經營狀況(在此種情況下被認可的範圍內),無論是因爲擁有或租賃財產或從事業務,並且除了無被合法資格或在良好的經營狀況(在此種情況下被認可的範圍內)這樣的要求會導致本公司發生重大不利變化的情況外,幾乎所有情況下公司均已成爲外國法人;公司在本註冊聲明、銷售時間的展望和招股說明書中披露的不同於上述情況的子公司(對於本協議而言,在證券法規定的規則405下定義)的每個子公司,均已合法依法註冊或組織,在所在管轄區域的法律下作爲公司、合夥企業或有限責任公司有效地存在,並擁有(公司或其他)的權力和機關,以擁有、租賃和經營其財產,並按照本註冊聲明、銷售時間的展望和招股說明書中所述開展業務。公司的每個子公司均已合法獲得外國公司、合夥企業或有限責任公司,取得資格在所需的司法管轄區內開展業務,並且在要求的任何司法管轄區內處於良好的經營狀況(在此種情況下被認可的範圍內),無論是因爲擁有或租賃財產或從事業務,並且除了無被合法資格或在良好的經營狀況(在此種情況下被認可的範圍內)這樣的要求會導致本公司發生重大不利變化的情況外,幾乎所有情況下公司均已成爲外國法人;每個公司的子公司已合法授權和已發行的資本證券或其他股份或所有權利益,已全部得到授權發行,並已完全支付和不可追索,並被公司(或直接或間接)或其子公司所擁有,不受任何抵押、質押、留置、債權或不利主張的限制。任何子公司的已發行的股權或股權利益沒有違反該子公司任何股東的優先權或類似權利。每個子公司的組織或組建文件在實施適用於其設立法域的法律要求的資料方面,均是完整的。除了公司的年度報告Form 10-K的附表21列出的子公司外,公司不直接或間接地擁有或控制或其他佔有任何公司、協會或其他實體。. Each of the Company and its Subsidiaries has been duly incorporated and is validly existing as a corporation in good standing under the laws of its jurisdiction of organization and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Prospectus and to enter into and perform its obligations under this Agreement, as applicable. The Company and its Subsidiaries are each duly qualified as a foreign corporation or foreign partnership to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except for such jurisdictions where the failure to so qualify or to be in good standing would not, individually or in the aggregate, result in a Material Adverse Change.
(p)
子公司. The subsidiaries set forth on 附表4 (統稱爲「)」,在適用的法定時效期滿前持續有效。在適用的存續期限指定於本文件所規定的存續期限到期之前,未經在此之前規定通知提出有關任何陳述和保證的賠償要求,將無效,且任何對賠償的權利在該存續期限屆滿後已不可撤銷地放棄。對於此類侵犯所提出的可賠償損失的任何正確要求,應該在此處規定的存續期限內及時提出。子公司”), are the Company’s only significant subsidiaries (as such term is defined in Rule 1‑02 of Regulation S‑X promulgated by the Commission). Except as set forth in the Registration Statement and in the Prospectus, the Company owns, directly or indirectly, all of the equity interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal or other restriction, and all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and free of preemptive and similar rights. No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such Subsidiary’s capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary’s property or assets to the Company or any other Subsidiary of the Company.
(q)
股本事項. The Common Stock conforms in all material respects to the description thereof contained in the Prospectus. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with federal and state securities laws. None of the outstanding shares of Common Stock were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company other than those accurately described in all material respects in the Prospectus. The description of the Company’s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Prospectus accurately and fairly presents in all material respects the information required to be shown with respect to such plans, arrangements, options and rights.
(r)
不存在違反現有協議或安排的行爲;無需獲得其他授權或批准. Neither the Company nor any of its Subsidiaries is in violation of its charter or by-laws or is in default (or, with the giving of notice or lapse of time, would be in default) (“違約”) under any indenture, mortgage, loan or credit agreement, note, contract, franchise, lease or other instrument to which the Company or any of its Subsidiaries is a party or by which it may be bound, or to which any of the property or assets of the Company or any of its Subsidiaries is subject (each, an “現有的設備”), except for such Defaults as would not, individually or in the aggregate, result in a Material Adverse Change. The Company’s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Prospectus (i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or by-laws of the Company or any of its Subsidiaries, (ii) will not conflict with or constitute a breach of, or Default under, or result in the creation or imposition of any lien, charge or encumbrance
無實質性行動或訴訟. Except as disclosed in the Registration Statement or the Prospectus, there are no legal or governmental actions, suits or proceedings pending or, to the best of the Company’s knowledge, threatened (i) against or affecting the Company or any of its Subsidiaries, (ii) which has as the subject thereof any officer or director of, or property owned or leased by, the Company or any of its Subsidiaries or (iii) relating to environmental or discrimination matters, where in any such case would reasonably be expected to result in a Material Adverse Change or adversely affect the consummation of the transactions contemplated by this Agreement. No labor problem or dispute with the employees of the Company or any of its Subsidiaries exists or, to the Company’s knowledge, is threatened or imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers, contractors or customers, in each case that might, individually or in the aggregate, have a Material Adverse Change. To the Company’s knowledge, no union organizing activities are currently taking place concerning the employees of the Company or any of its Subsidiaries, and there has been no material violation of any federal, state, local or foreign law relating to discrimination in the hiring, promotion or pay of employees, any applicable wage or hour laws or any provision of the Employee Retirement Income Security Act of 1974, as amended, or the rules and regulations promulgated thereunder concerning the employees of the Company or any of its Subsidiaries.
(u)
所有必要的許可證等. The Company and its Subsidiaries each have all licenses, certifications, permits, franchises, approvals, clearances, exemptions, registrations and other regulatory authorizations (“許可證”) from governmental authorities as are necessary to conduct its businesses as currently conducted and to own, lease and operate its properties in the manner described in the Prospectus except for such, individually or in the aggregate, would reasonably be expected to have a Material Adverse Change. There is no claim, proceeding or controversy, pending or, to the knowledge of the Company, threatened, involving the status of or sanctions under any of the Permits which,
Except as has been disclosed to Cantor or is not material to the analysis under any Sanctions, to the Company’s knowledge the Company and its Subsidiaries have not engaged in any dealings or transactions with or for the benefit of a Sanctioned Person, or with or in a Sanctioned
12
Country, since April 24, 2019, nor do the Company and its Subsidiaries have any plans to increase its dealings or transactions with Sanctioned Persons, or with or in Sanctioned Countries.
(hh)
公司的會計制度。. The Company and each of its Subsidiaries maintains a system of 「internal control over financial reporting」 (as such term is defined in Rule 13a-15(f) of the General Rules and Regulations under the Exchange Act (the “Exchange Act Rules”)) that complies with the requirements of the Exchange Act and has been designed by their respective principal executive and principal financial officers, or under their supervision, to provide reasonable assurances that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company’s internal control over financial reporting is effective at the reasonable assurance level. Except as described in the Prospectus, since the end of the Company’s most recent audited fiscal year, there has been (A) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (B) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
遵守環保法律法規公司或其任何子公司(A)並未違反任何關於使用、處理、釋放有害化學品、毒性物質或放射性和生物材料,或任何關於環境保護或恢復或人類接觸有害化學品、毒性物質或放射性和生物材料的任何政府機構國內或國外法令、規章、決定或命令(統稱“環保母基”), and (B) owns or operates
13
any real property contaminated with any substance that is subject to any Environmental Laws, is not liable for any off-site disposal or contamination pursuant to any Environmental Laws, nor is subject to any claim relating to any Environmental Laws, which violation, contamination, liability or claim, in each case as would individually or in the aggregate have a Material Adverse Change; and the Company is not aware of any pending investigation which might lead to such a claim.
(ll)
知識產權. Except to the extent described in the Prospectus, the Company and each of its Subsidiaries owns, licenses, or otherwise has rights in all United States and foreign patents, trademarks, service marks, tradenames, copyrights, trade secrets and other proprietary rights necessary for the conduct of its business as currently carried on and as proposed to be carried on as described in the Prospectus (collectively and together with any applications or registrations for the foregoing, the “知識產權”). Except as specifically described in the Prospectus, (i) no third parties have obtained, or will reasonably be expected to be able to establish, any interest in or rights to any such Intellectual Property from the Company or any of its Subsidiaries, other than licenses granted in the ordinary course; (ii) to the Company’s knowledge, there is no infringement, misappropriation, or other violation by third parties of any such Intellectual Property; (iii) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s or any of its Subsidiaries’ rights in or to any such Intellectual Property, and the Company is unaware of any facts which would form a basis for any such claim; (iv) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, enforceability, or scope of any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (v) there is no prior, pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company or any of its Subsidiaries has infringed, misappropriated or violated, does infringe, misappropriate or otherwise violate, or would upon further development or commercialization of any product, product candidates, or services described in the Prospectus as under development, infringe, misappropriate or violate, any Intellectual Property of others, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (vi) to the Company’s knowledge there is no patent or patent application that contains claims that would interfere with or cover (or may interfere with or cover) the claims of any patent or patent application included in the Company Intellectual Property described in the Prospectus or the Disclosure Package or that interferes with the issued or pending claims of any such Intellectual Property; (vii) there is no prior art or public or commercial activity of which the Company is aware that may render any patent held by the Company or any of its Subsidiaries invalid or that would preclude the issuance of any patent on any patent application held by the Company or any of its Subsidiaries unpatentable which has not been disclosed to the U.S. Patent and Trademark Office or, if required to be disclosed, to a relevant foreign patent authority, as the case may be; (viii) neither the Company nor any of its Subsidiaries has committed any act or omitted to undertake any act the effect of such commission or omission would render the Intellectual Property invalid or unenforceable in whole or in part; (ix) to the Company’s knowledge, the claims of the issued patents included in its and its Subsidiaries’ Intellectual Property are valid and enforceable and the Company is unaware of any facts that would preclude the issuance of a valid and enforceable patent on any pending application included in the Company’s or any of its Subsidiaries’ Intellectual Property; (x) the manufacture, use and sale of the products or product candidates described in the Prospectus as under development by the Company fall within the scope of one or more claims of the patents or patent applications included in the Company’s Intellectual Property; (xi) the Company has taken reasonable steps necessary to secure the interest of the Company and its Subsidiaries in their respective Intellectual Property purported to be owned by the Company or any of its Subsidiaries from any employees, consultants, agents or contractors that developed (in whole or in part) such Intellectual Property; (xii) there are no outstanding options, licenses
臨床試驗. Except to the extent disclosed in the Registration Statement and the Prospectus, the pre-clinical, clinical, and other studies, tests and research conducted by or on behalf of or sponsored by the Company (and with respect to such studies, tests, and research sponsored by third parties, to the Company’s knowledge) are, and at all times have been, conducted in all material respects in accordance with the FD&C Act and the regulations and guidelines promulgated thereunder, including all U.S. Food and Drug Administration (“FDA”) regulations and guidelines governing clinical trials, including good laboratory practice and good clinical practice regulations, as well as other applicable federal, state, local and foreign (whether national or regional) Laws, and consistent with the protocols submitted to the FDA or any other applicable regulatory authority and procedures and controls generally used by qualified experts in the pre-clinical and clinical development of drugs. The descriptions of the results of such trials, studies, tests and research are accurate and complete in all material respects and fairly present the data derived from such trials, studies, tests and research, and the Company does not have any knowledge of any other trials, studies, tests or research the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement and the Prospectus. Except to the extent disclosed in the Registration Statement and the Prospectus, no safety concerns have emerged with respect to any clinical or pre-clinical trials, studies, tests or research that are described in the Registration Statement and the Prospectus, or the results of which are referred to in the Registration Statement and the Prospectus, and the Company has reported all adverse events and potential safety concerns that are required by Law to be reported to FDA or any other applicable regulatory authority. Except to the extent disclosed in the Registration Statement and the Prospectus, neither the Company nor any of its Subsidiaries has received any notices or other correspondence from the FDA or any other Governmental Authority with respect to any clinical or pre-clinical trials, studies, tests or research that are described in the Registration Statement and the
網絡安全概念. The Company and its Subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT系統公司及其子公司已實施並保持了商業上合理的物理、技術和管理控制、政策、程序和防護措施,以維護和保護它們的重要機密信息以及所有IT系統和數據的完整性、持續運行、冗餘和安全性。 這些信息包括所有「個人數據」(如下所定義)以及在與其業務有關時使用的所有敏感、機密或受監管的數據。蘋果CEO庫克大規模沽出股票,套現逾3億港元。在與其業務有關時使用的所有敏感、機密或受監管數據。個人數據「個人數據」指(i)自然人的姓名、街道地址、電話號碼、電子郵件地址、照片、社會保障號碼或納稅識別號、駕駛執照號碼、護照號碼、信用卡號碼、銀行信息或客戶或帳戶號碼;(ii)根據聯邦貿易委員會法修正案確定爲「個人身份信息」的任何信息;(iii)GDPR所定義的「個人數據」;(iv)根據《1996年健康保險移植和責任法案》,由《2009年衛生信息技術經濟和臨床健康法》修正的《醫療保險便攜和責任法案》下確定爲「受保護健康信息」的任何信息(統稱「受保護健康信息」)。HIPAA依照加州消費者隱私權法規定義的任何「個人信息」CCPA以及任何其他信息,可用於確定自然人或其家庭的身份,或允許收集或分析任何與已確定人士的健康或性取向相關的數據。未發生任何泄漏、違規、中斷或未經授權使用或訪問同等情況,除非已無實質成本或責任或通知其他人的義務已得到解決;也沒有內部審查或調查涉及同等情況的事件。公司及其子公司目前在所有適用法律或法規以及任何法院、仲裁員、政府或監管機構的判決、命令、規則和法規、內部政策和與隱私和安全有關的合同義務方面保持實質性合規,這涉及IT系統、機密數據和個人數據的保護,以及保護這些IT系統、機密數據和個人數據免受未經授權的使用、訪問、挪用或修改。
費用無論是否完成本協議下的交易或終止本協議,根據本協議的規定,公司將支付一下全部費用,包括但不限於:(i)準備、印刷和歸檔註冊聲明及其每一份修訂和補充資料,每份招股說明書及其每一份修訂和補充資料的費用,(ii)準備、發行和交付股票的費用,(iii)將股票按照本協議第7(d)款的規定合規地進行投資交易所需支付的費用,包括申報費用(任何與TD Cowen諮詢費或支出相關的費用將由TD Cowen支付,除非在(vii)項中另有規定),(iv)印刷並向TD Cowen提供招股說明書及其任何修訂或補充資料的副本以及本協議和任何條款協議的費用,(v)上市或交易股票所需的費用和支出 第11節. 修改和終止。
(a) 除適用法律禁止的範圍外,並且除非獎項協議或本2020年計劃另有明示規定,行政管理者可隨時修改、改變、暫停、停止或終止本2020年計劃或此事項或此類事項的一部分; 根據本協議,甲方將支付一切與履行其義務有關的費用,包括但不限於(i)註冊文件及其每一次修訂和補充文件的準備、印刷和歸檔費用,每份招股說明書及其每一次修訂和補充文件的費用,(ii)配售股份的準備、發行和交付費用,(iii)根據本協議的規定將配售股份按證券法規定合法上市的費用。 本協議第7(d)項規定的相關證券法所需的費用,包括申報費用(任何與TD Cowen有關的律師費或費用除外,在(vii)項中除外) of this Agreement, including filing fees (provided, however, that any fees or disbursements of counsel for Cantor in connection therewith shall be paid by Cantor except as set forth in (vii) below), (iv) the printing and delivery to Cantor of copies of the Prospectus and any amendments or supplements thereto, and of this Agreement, (v) the fees and expenses incurred in connection with the listing or qualification of the Placement Shares for trading on Nasdaq, (vi) the filing fees and expenses, if any, of the Commission, (vii) the filing fees and associated legal expenses of the Cantor’s outside counsel (not to exceed $10,000, collectively) for filings with the FINRA Corporate Financing Department and, (viii) the reasonable fees and disbursements of the Cantor’s counsel (a) in an amount not to exceed $75,000 collectively in connection with the execution of this Agreement and filing of the prospectus supplement in connection with the Placement Shares dated November 6, 2024 (the “November 2024 Prospectus Supplement”), (b) in an amount not to exceed $25,000 thereafter payable in connection with each Representation Date involving the filing of an annual report on Form 10-k or quarterly reports on Form 10-Q with respect to which the Company is obligated to deliver a certificate pursuant to 蘋果CEO庫克大規模出售股票,從中獲得逾3億港元。 對於不適用任何豁免和不包括本協議日期的情況,以及(c)每個「刷新」項目(新註冊聲明、招股說明書或招股說明書附錄與本協議相關的配售股份和/或根據本協議執行的修訂,但不包括2024年11月招股說明書的提交)的金額不得超過25,000美元。
(h)
使用所得款項。公司將根據招股說明書中「資金用途」部分中描述的內容使用淨收益。
(i)
其他銷售通知和同意。在根據本處通知給予的任何配售通知的有效期內,在根據本處通知給予的配售通知終止後的五個交易日內,公司應在其出售、合同銷售、銷售、授予任何出售選擇權或以任何其他形式處置任何普通股份(不包括根據本協議規定的配售股份)或轉換爲、或可兌換成普通股的證券、認股權證或任何購買或取得普通股權益的權利之前,儘可能迅速向康騰提供通知,並且未經康騰的事先書面同意,公司不得在本協議終止及最後的結算日期之前六十(60)日後根據本通知出售的配售股份方面直接或間接以其他「市價」或連續股權交易方式出售、銷售、合同銷售、授予任何出售選擇權或以任何其他方式處置任何普通股(不包括根據本協議規定的配售股份)或轉換爲、可兌換成普通股的證券、認股權證或任何購買或取得普通股權益的權利。th) 。在根據該配售通知出售的配售股份的最終結算日期後立即的第六十(60)日及後期,不得在未經有關配售通知出售的配售股份方面的前提下,未經康騰的事先書面同意,公司不得直接或間接地以其他「市價」或連續股權交易方式報價出售、出售、合同出售、授出任何銷售選擇權或以其他方式處置任何普通股(不包括根據本協議規定的配售股份)或轉換成、或可兌換成普通股的證券、認股權證或任何購買或取得普通股權益的權利,直至本協議終止並且在最後結算日期後立即的第六十(60)日爲止。 在每種情況下,該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時;在(i)發行、授予或出售普通股、股票期權或其他權益獎勵以購買或取得普通股或在實施股票期權、股票獎勵或其他描述於招股說明書的股票期權計劃或安排中的普通股或所獲得普通股行權證、股票期權或其他在生效或未行使中的權益下所發行的、(ii)與收購、合併或出售或購買資產有關的證券發行,或(iii)根據公司不時可能採納且提前告知 Cantor 的任何股利再投資計劃中發行或出售普通股,或者(iv)在發行通知書交換、轉換或贖回證券或行使認股權證、股票期權或其他權利下所發行的任何普通股等情況下,不需要提供此類通知或限制。
21
股票或其他股票期權以及根據本協議中提及的任何股票期權、股票獎勵或其他股票計劃或安排行使股票期權或其他股票獎勵實施時可發行的普通股或股票。涉及併購、合併、出售或購買資產的證券發行,或公司可能不時採納並向 Cantor 提前披露的任何股利再投資計劃中發行或銷售普通股等。
(j)
情況變更在發出放置通知書之前(如果事前不知曉,則在放置通知書掛起期間),公司將在接到通知或獲得相關知識後,及時告知 Cantor 任何可能改變或對根據本協議向 Cantor 提供的任何意見、證書、函或其他文件產生實質性影響的信息或事實。
(k)
盡審慎調查合作在本協議涉及的交易中,公司將積極配合 Cantor 或其代理進行的任何合理盡職調查審核,包括但不限於提供信息、提供文件並在公司主要辦公室與正常營業時間內提供高級公司管理人員,以應 Cantor 的合理請求。
(l)
關於配售股份的必要文件. The Company agrees that on such dates as the Securities Act shall require, the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act (each and every filing under Rule 424(b), a “歸檔日期”), which prospectus supplement will set forth, within the relevant period, the amount of Placement Shares sold through Cantor, the Net Proceeds to the Company and the compensation payable by the Company to Cantor with respect to such Placement Shares, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market.
(m)
代表日期;證書. On or prior to the date of the first Placement Notice and each time during the term of this Agreement the Company (i) amends or supplements the Registration Statement or the Prospectus relating to the Placement Shares (other than a prospectus supplement filed in accordance with 本協議第7(l)款 of this Agreement) by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of document(s) by reference to the Registration Statement or the Prospectus relating to the Placement Shares; (ii) files an Annual Report on Form 10-k under the Exchange Act; (iii) files its Quarterly Reports on Form 10-Q under the Exchange Act; or (iv) files a Current Report on Form 8-k containing amended financial information (other than an earnings release or other information 「furnished」 and not 「filed」) under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a “表示日期公司應向凱恩提供證書(但僅針對以上第(iv)款的情況,即(1)存在待發出的配售通知,並且(2)凱恩合理判斷這份8-k表中的信息對普通股持有人具有重要性),表格格式如附件所示, 展品7(m) 如凱恩要求,在任何代表日期後的一個(1)交易日內提供此證書的要求。根據本協議提供證書的要求 蘋果CEO庫克大規模出售股票,從中獲得逾3億港元。 在沒有待發出的配售通知的情況下發生的任何代表日期上,此要求將被豁免,該豁免將持續直至公司根據本協議發送配售通知的日期(對於當季度而言,此日期將被視爲代表日期)及下一個即將發生的代表日期之間的先行
法律意見 蘋果CEO庫克大規模出售股票,從中獲得逾3億港元。 for which no waiver is applicable, the Company shall cause to be furnished to Cantor (i) a written opinion and 「100億.5」 negative assurance statement of Cooley LLP (“公司律師”), or other counsel reasonably satisfactory to Cantor, in form and substance satisfactory to Cantor and its counsel and (ii) a written opinion of Covington & Burling LLP, as intellectual property counsel for the Company, in such form and substance satisfactory to Cantor and its counsel, each such opinion, dated the date that such opinion is required to be delivered, substantially similar to the form previously agreed to with counsel to Cantor in the negotiation of this Agreement, or in such other form reasonably satisfactory to counsel to Cantor at the time that each such opinion is required to be delivered, respectively, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; 然而, the Company shall not be required to furnish any such opinion or statement if the Company does not intend to deliver a Placement Notice in such calendar quarter until such time as the Company delivers its next Placement Notice; and 企業或非公司子公司欠公司或公司子公司的債務或其他義務所擔保的抵押品;, 但是, that in lieu of such opinions for subsequent Representation Dates, counsel may furnish Cantor with a letter (a “公司和代理根據本協議中該等股份的條款和條件,特此聲明並同意,公司和代理未作出並將不作出任何與股份相關的要約,該要約構成根據證券法規定的「發行人自由書面說明書」(Rule 433下定義)或其他根據證券法規定的「自由書面說明書」(Rule 405下定義),無需向委員會提交,除允許的自由書面說明書外。”) to the effect that Cantor may rely on a prior opinion delivered under this 第7(n)條 to the same extent as if it were dated the date of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).
(o)
保全信函. On or prior to the date of the first Placement Notice and within one (1) Trading Day of each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to 蘋果CEO庫克大規模出售股票,從中獲得逾3億港元。 for which no waiver is applicable, the Company shall cause its independent accountants to furnish to Cantor a letter (the “安慰函),日期爲交付安慰函之日,此函滿足本第7(o)節規定的要求; 在每種情況下,該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時;如Cantor要求,公司應在發生任何重大交易或事件,包括公司財務報表重述的發生之日起十(10)個交易日內向Cantor提供一份安慰函。公司獨立註冊的外部會計師事務所出具的安慰函應符合Cantor合理滿意的形式和內容,(i)確認他們是《證券法》和上市公司會計監督委員會有關獨立註冊的外部會計師事務所的意義之內的獨立註冊的外部會計師事務所,(ii)陳述截至該日,該事務所對財務信息和其他通常由會計師在向Cantor提供與已登記公司發行有關的「安慰函」時涵蓋的事項的結論和發現(第一份此類函件爲“ 初始舒適函)並(iii)更新最初的安慰函,其中包括在最初的安慰函中應包括的任何信息,同時進行必要的修改以與當日的註冊聲明和招股說明書相關並根據需要進行修改和補充的關係。
公司同意對TD Cowen、其附屬機構及其各自的董事、高管、合夥人、僱員和代理人,以及任何一個(i)根據《證券法》第15條或《交易法》第20條的規定控制TD Cowen或(ii)受TD Cowen 控制或與TD Cowen處於共同控制下的人,對任何和所有損失、索賠、負債、支出和損害(包括任何和所有合理的調查、法律和其他費用,以及任何根據《證券法》、《交易法》或其他聯邦或州法規定、在普通法下或以其他方式進行支付的金額(在此規定爲「結算金額」))進行賠償和保護,只要這些損失、索賠、負債、支出或損害在直接或間接上基於(x)註冊聲明或招股書或對註冊聲明或招股書的任何修改或補充或任何資料招股書或其他文件中所述的任何虛假陳述或被指稱的虛假陳述,或者(y)未能披露在註冊聲明或招股書或對註冊聲明或招股書的任何修改或補充或任何資料招股書或其他文件中,只要此類損失、索賠、負債、支出或損害構成違反或構成違背《證券法》、《交易法》或其他聯邦或州法規定或普通法的行爲。公司同意對康泰、康泰的董事、高管、合夥人、僱員和代理商以及根據證券法第15條或交易法第20條的定義控制康泰的任何人,或者受康泰控制或與其共同控制的任何人提供補償並使其免受損害(“康泰附屬公司”) from and against any and all losses, claims, liabilities, expenses and damages (including, but not limited to, any and all reasonable investigative, legal and other expenses incurred in connection with, and any and all
26
amounts paid in settlement (in accordance with 此) of, any action, suit or proceeding between any of the indemnified parties and any indemnifying parties or between any indemnified party and any third party, or otherwise, or any claim asserted), as and when incurred, to which Cantor, or any such person, may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out of or are based, directly or indirectly, on (x) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus or any amendment or supplement to the Registration Statement or the Prospectus or in any free writing prospectus or in any application or other document executed by or on behalf of the Company or based on written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Common Stock under the securities laws thereof or filed with the Commission or (y) the omission or alleged omission to state in any such document a material fact required to be stated in it or necessary to make the statements in it not misleading; 在每種情況下,該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時;, 但是, that this indemnity agreement shall not apply to the extent that such loss, claim, liability, expense or damage arises from the sale of the Placement Shares pursuant to this Agreement and is caused directly or indirectly by an untrue statement or omission made in reliance upon and in conformity with the Agent’s Information (as defined below). This indemnity agreement will be in addition to any liability that the Company might otherwise have.
(b)
Cantor IndemnificationCantor同意對公司及其董事以及簽署註冊聲明的公司每位官員以及公司控制者(根據《證券法》第15條或《交易法》第20條的含義)承擔責任並使其免受任何損失、責任、索賠、損害和費用,均在包含的賠償中描述 本條款第9(a)節(公司承擔義務賠償)規定的權利和義務之外,如果公司或其代理未能履行在交割日交付授權股份的義務而不是由於TD Cowen的原因,公司同意(i)保護TD Cowen免失或對TD Cowen遭受的任何損失、索賠、損害、合理且可證明的費用(包括律師費和其他費用)承擔責任,並(ii)支付任何佣金、折價或其他報酬給TD Cowen(無需重複)。如未發生違約情況,TD Cowen將享有按照協議應得到的佣金、折價或其他報酬。,如遇到的,但僅就註冊聲明(或其任何修訂)、招股書(或任何修訂或補充)、任何發行人自由書面招股書(或任何修訂或補充)中依賴並符合代理商信息而進行的不實陳述或遺漏,或被指控的不實陳述或遺漏而言。公司特此承認Cantor向公司明確提供供在註冊聲明、招股書或任何發行人自由書面招股書(或其任何修訂或補充)中使用的唯一信息,即招股書「分銷計劃」標題下最後兩段中列出的聲明(“代理商信息僅指招股說明書中「配售計劃」一欄第六段和第十段第三句話中的以下信息。”).
陳述和協議在交付後仍然有效本協議中包含的賠償和追償協議,以及公司在此處或根據本協議交付的證書中的全部陳述和保證,將在其各自的日期不受以下事項的影響而繼續生效,無論這些事項是:(i) TD Cowen、任何控制人或公司(或其任何董事、高管或控制人)的調查,(ii) 股份的交付和接受以及相應的支付,或(iii) 本協議的任何終止。 第九部分 of this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of Cantor, any controlling persons, or the Company (or any of their respective officers, directors, employees or controlling persons), (ii) delivery and acceptance of the Placement Shares sold by Cantor and payment therefor or (iii) any termination of this Agreement.
11.
終止.
(a)
Cantor shall have the right by giving notice as hereinafter specified at any time to terminate this Agreement if (i) any Material Adverse Change, or any development that could reasonably be expected to result in a Material Adverse Change has occurred that, in the reasonable judgment of Cantor, may materially impair the ability of Cantor to sell the Placement Shares hereunder, (ii) the Company shall have failed, refused or been unable to perform any agreement on its part to be performed hereunder; 不過 in the case of any failure of the Company to deliver (or cause another person to deliver) any certification, opinion, or letter required under 第7(m)節、第7(o)節,, 7(n),或關注 @EVERFI。7(o), Cantor’s right to terminate shall not arise unless such failure to deliver (or cause to be delivered) continues for more than thirty (30) days from the date such delivery was required; or (iii) any other condition of Cantor’s obligations hereunder is not fulfilled, or (iv), any suspension or limitation of
An electronic communication (“電子公告”將被視爲本第12條的書面通知,如果發送至接收方在單獨封面下指定的電子郵件地址。電子通知應在發送方收到接收方收到的回執驗證時視爲已接收。接收電子通知的任何一方可要求並有權以紙質形式收到通知,非電子形式送達(“非電子通知e”)發送給請求方,應在收到書面要求非電子通知的十(10)日內發送給請求方。
In the event that Cantor is a Covered Entity and Cantor or a BHC Act Affiliate of Cantor becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against Cantor are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.
The undersigned, the duly qualified and elected [ ], of SCYNEXIS, Inc. (“公司作爲該公司的代表,一家特拉華州的公司,在該公司和TD Securities (USA) LLC(下文簡稱"_____________")於2024年8月7日簽訂的銷售協議中,根據該協議進行證明。 蘋果CEO庫克大規模出售股票,從中獲得逾3億港元。 of the Sales Agreement dated November 6, 2024 (the “買賣協議”) between the Company and Cantor Fitzgerald & Co., that to the best of the knowledge of the undersigned.
(i) The representations and warranties of the Company in 第6節 的銷售協議(A)在與重大性或重大不利變化相關的對其的真實性的限定和例外情況下,在此日期和此日期與其明確表達一樣,是真實和正確的,但是那些僅適用於某個特定日期並在該日期是真實和正確的陳述和保證除外;以及(B)在不受任何限定或例外情況的情況下,自此日期以來,在所有重要方面與此日期與其明確表達一樣,是真實和正確的,但是那些僅適用於某個特定日期並在該日期是真實和正確的陳述和保證除外;和
(ii) 公司已在此之前或此日期履行了所有銷售協議中應履行或滿足的所有協議和條件。
Capitalized terms used herein without definition shall have the meanings given to such terms in the Sales Agreement.